X

Trial Profile

Efficacy, Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
Indications Cervical intraepithelial neoplasia; Human papillomavirus infections
Focus Registrational; Therapeutic Use
Sponsors GlaxoSmithKline; GSK

Most Recent Events

28 Jul 2016 Status changed from active, no longer recruiting to completed.
05 May 2016 Planned End Date changed from 1 Jan 2016 to 1 Nov 2016.
17 Apr 2014 Planned End Date changed from 1 Feb 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com